Yurpeak 12.5mg KwikPen

Yurpeak 12.5mg KwikPen is a prescription injectable medication containing Tirzepatide 12.5mg per 0.6ml as its active pharmaceutical ingredient. It belongs to the class of dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. The medicine is designed to support blood glucose management in adults with type 2 diabetes and chronic weight management in eligible adults, alongside appropriate dietary and lifestyle modifications.

Yurpeak is supplied in a multi-dose, single-patient-use prefilled KwikPen device. Each pen contains 2.4ml of solution and provides four fixed doses of 12.5mg, administered once weekly as prescribed by a healthcare professional.

Composition and Strength

Brand Name: Yurpeak

Active Ingredient: Tirzepatide

Strength: 12.5mg/0.6ml

Dosage Form: Solution for Injection

Presentation: Multi-dose Prefilled KwikPen

Total Pen Volume: 2.4ml

Doses Per Pen: Four fixed doses

Route of Administration: Subcutaneous Injection

Uses and Therapeutic Indications

Yurpeak 12.5mg KwikPen is used under medical supervision for the following therapeutic purposes:

1. Type 2 Diabetes Management

Tirzepatide helps improve blood glucose control in adults with type 2 diabetes. It works through GIP and GLP-1 receptor activation, supporting glucose-dependent insulin secretion and helping regulate glucagon levels.

2. Chronic Weight Management

Tirzepatide may support weight reduction and long-term weight management in eligible adults living with obesity or overweight accompanied by at least one weight-related medical condition. It is used alongside a reduced-calorie diet and increased physical activity.

Mechanism of Action

Tirzepatide acts on two incretin hormone receptors: GIP and GLP-1. These hormones participate in regulating glucose metabolism and appetite.

Its mechanism of action includes:

Enhancing insulin secretion in response to elevated blood glucose.

Reducing glucagon secretion when blood glucose levels are elevated.

Delaying gastric emptying, particularly during initial treatment.

Influencing appetite regulation and food intake.

These combined actions help improve glycaemic control and support weight management.

Dosage and Administration

Yurpeak 12.5mg KwikPen is administered through subcutaneous injection, generally once weekly. The prescribed strength and treatment schedule must be determined by a qualified healthcare professional.

The injection is administered into approved subcutaneous injection sites, such as the abdomen or thigh. The upper arm may also be used with assistance. Injection sites should be rotated as instructed.

Patients should follow the official Instructions for Use supplied with the KwikPen. The pen must never be shared between individuals, even when a new needle is used.

Possible Side Effects

Commonly reported adverse reactions associated with tirzepatide include:

Nausea

Vomiting

Diarrhoea

Constipation

Abdominal discomfort

Decreased appetite

Indigestion

Severe or persistent gastrointestinal symptoms, allergic reactions, symptoms of pancreatitis or other unusual reactions require prompt medical assessment.

Warnings and Precautions

Yurpeak should be used only under appropriate medical supervision. Patients should inform their healthcare professional about existing medical conditions and all medicines being taken.

Particular attention is required regarding pancreatitis, gallbladder disorders, dehydration, hypoglycaemia when used with insulin or insulin secretagogues, and serious hypersensitivity reactions.

Tirzepatide is contraindicated in patients with a known serious hypersensitivity to its ingredients. The applicable prescribing information should also be consulted regarding thyroid C-cell tumour warnings and other contraindications.

Storage Information

Store Yurpeak 12.5mg KwikPen in accordance with the manufacturer's approved storage instructions. Refrigeration at 2°C to 8°C is generally required before use. Do not freeze the medication. Protect it from excessive heat and light, and refer to the accompanying patient information leaflet for in-use storage conditions.

Important Medical Information

Yurpeak 12.5mg KwikPen is a prescription medication. It should not be initiated, discontinued or adjusted without professional medical advice. The product information and approved prescribing instructions should always be consulted before administration.